Akers Biosciences revenues, gross profit up 10%, overhead lowered 10%

Akers Biosciences has announced the results for the first half 2017 in which it posted gross profit to be up 10% to $1,342,160, compared to the same period previous year, $1,217,634. As the total revenues moved up 10% for first 6 months of 2017 which were $1,865,112, compared to the 2016’s first half of $1,694,510, Akers Biosciences’s loss before income tax was reduced by 20% to $2,051,918, from first half in 2016, $2,517,861.

Read more

Akers Biosciences to market Heparin PF4 rapid test in Puerto Rico

Akers Biosciences, a developer of rapid health information technologies, has begun marketing its rapid test for heparin-induced thrombocytopenia (“HIT”) to the large number of hospital facilities in Puerto Rico as an extension of the company’s strategy to accelerate U.S. sales of its flagship product.

Read more